Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca sales decline slows as it waits for medicine to work

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2017 | 12:48pm CET
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

LONDON (Reuters) - AstraZeneca's (>> AstraZeneca) drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes.

LONDON (Reuters) - AstraZeneca's (>> AstraZeneca) drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes.

Product sales were down 3 percent compared with an 11 percent fall during the first half of the year. Emerging markets proved a bright spot, with Chinese sales up 12 percent, the company said on Thursday.

Chief Executive Pascal Soriot believes the drugmaker has reached a turning-point as its pipeline of new medicines starts to deliver and the impact of patent losses recedes. Consensus forecasts also point to a recovery in sales and profits from next year.

Still, the speed of AstraZeneca's turnaround remains uncertain as the No.2 British drugmaker goes head to head with industry giants like Roche (>> Roche Holding Ltd.), Bristol-Myers Squibb (>> Bristol-Myers Squibb Company) and Merck & Co (>> Merck and Company) in the fast-growing but fiercely competitive cancer drug market.

Total revenue rose 9 percent to $6.23 billion (£4.7 billion) in the quarter, helped by a $997 million payment from Merck, which struck a cancer drug partnership deal with the British group in July. Sales of Crestor, while down 16 percent, were also higher than expected.

That was not enough to stop a fall in core earnings per share (EPS), which exclude some items, of 15 percent to $1.12. But the overall results were better than expected and the shares had risen around 1 percent by 1130 GMT.

Industry analysts, on average, had forecast quarterly earnings of $1.04 and revenue of $5.95 billion, according to Thomson Reuters data.

For the full year, AstraZeneca said it expected 2017 core EPS to be "towards the favourable end of the guidance range of a low to mid teens percentage decline".

Soriot said he remained confident AstraZeneca could achieve annual revenue of more than $40 billion in 2023, despite scepticism among analysts like Trinity Delta's Mick Cooper who said it was "difficult" to see how this would be done.

Soriot first gave a bullish long-term forecast of 2023 revenue hitting $45 billion back in 2014, as he fended off a takeover attempt by Pfizer (>> Pfizer). Since then, a stronger dollar has shifted the target slightly but Soriot said the expectation in constant exchange rates had not changed.

"Our long-range plan so far reconfirms that we can get to the $40-41 billion dollars at today's currency rates that we communicated back in 2014," he said.


Results from drug trials remain critical.

AstraZeneca suffered the biggest ever daily fall in its shares three months ago, following the initial failure of a key lung cancer trial dubbed Mystic.

But it has since rebuilt investor expectations, helped by impressive data from two other lung cancer trials, involving the drugs Tagrisso and Imfinzi, that were presented at a medical congress in Madrid in September.

And just last week it won early U.S. approval for Calquence, marking its first entry into the blood cancer market.

However, results from another immunotherapy lung cancer trial called Arctic have been delayed again and are now not expected until the first half of 2018.

AstraZeneca is also refilling its drug pipeline in other areas, such as respiratory medicine. A new drug for severe asthma is awaiting U.S. approval by the end of this year and could get an approval recommendation in Europe as early as Friday.

(Reporting by Ben Hirschler; Editing by Keith Weir and Mark Potter)

By Ben Hirschler

Valeurs citées dans l'article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.22% 66.53 Delayed Quote.6.64%
MERCK AND COMPANY -0.78% 54.55 Delayed Quote.-0.50%
PFIZER -0.69% 35.76 Delayed Quote.-2.84%
ROCHE HOLDING LTD. -0.18% 223.5 Delayed Quote.-9.37%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
10:07pASTRAZENECA : U.S. health officials reverse stance on AstraZeneca's flu vaccine
09:08pASTRAZENECA : Announces Renewed Recommendation and Availability of FLUMIST QUADR..
08:50pASTRAZENECA : US panel says it's OK to use nasal spray flu vaccine again
02/20MERCK AND : Groundbreaking lung cancer approval a big boost for AZs Imfinzi
02/19ASTRAZENECA : European indices gain tracking Asian equities
02/19MERCK AND : - Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Ne..
02/19ASTRAZENECA : FDA grants EAP designation to Guardant's NGS-based liquid biopsy
02/19ASTRAZENECA : US FDA approves Imfinzi for unresectable Stage III non-small cell ..
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
02/19ASTRAZENECA : Cell Lung Cancer Treatment Imfinzi Gets FDA Approval
More news
News from SeekingAlpha
03:26pCDC on board with AstraZeneca's Quadrivalent flu vaccine for next year 
11:49aYOUR DAILY PHARMA SCOOP : Portola Update, Wave Life Sciences To Collaborate With.. 
02/20Ionis out-licenses kidney disease candidate to AstraZeneca for up to $330M 
02/19AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In 
02/18BioSci Rounds Report For Feb. 16, 2018 
Financials ($)
Sales 2018 22 326 M
EBIT 2018 5 645 M
Net income 2018 2 145 M
Debt 2018 14 000 M
Yield 2018 4,16%
P/E ratio 2018 33,05
P/E ratio 2019 26,18
EV / Sales 2018 4,38x
EV / Sales 2019 4,12x
Capitalization 83 737 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 72,8 $
Spread / Average Target 10%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-7.96%83 737
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%226 667
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 826
MERCK AND COMPANY-0.50%153 359